Fig. 2
From: A monoclonal natural human IgM protects axons in the absence of remyelination
rHIgM12 treatment improves both horizontal and vertical activity in SJL mice during established demyelinating disease. Groups of SJL mice (N = 10 per treatment group) at 45 dpi were placed in activity monitoring boxes. Baseline measurements were collected over 8 days. Beginning at treatment (time zero), mice were monitored continuously over an additional 8 weeks. a, c correspond to horizontal activity and b, d correspond to vertical activity. a, b Original, unfiltered recordings for horizontal and vertical activity normalized to baseline; c, d third-order polynomial fitting of standardized z values normalized to baseline revealed improvement in both horizontal and vertical activity of the rHIgM12-treated group compared to the control IgM-treated group. Horizontal (e) and vertical (f) nocturnal activity of rHIgM12-treated mice compared to control IgM-treated mice significantly diverged above the x-axis (more activity) (p < 0.05) post-treatment. The pointwise lower 95 % confidence bands for the nocturnal activity are represented on the y-axis scale